Back to Search
Start Over
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
- Source :
-
International journal of laboratory hematology [Int J Lab Hematol] 2020 Apr; Vol. 42 (2), pp. 214-222. Date of Electronic Publication: 2020 Feb 10. - Publication Year :
- 2020
-
Abstract
- Introduction: To measure direct factor Xa inhibitor (apixaban, edoxaban, rivaroxaban) concentrations, dedicated chromogenic anti-Xa assays are recommended as suitable methods to provide rapid drug quantification. Moreover, the high-performance liquid chromatography with ultraviolet detection (HPLC-UV) is reported as a reliable quantitative technique. We investigated seven anti-Xa assays and an HPLC-UV method for measurement of apixaban and rivaroxaban levels in patients enrolled in the START-Register.<br />Methods: A total of 127 apixaban and 124 rivaroxaban samples were tested by HPLC-UV and the following anti-Xa assays: Biophen DiXaI and Heparin LRT (Hyphen BioMed), Berichrom and Innovance Heparin (Siemens), STA-Liquid Anti-Xa (Stago Diagnostics), Technochrom anti-Xa (Technoclone), and HemosIL Liquid Anti-Xa (Werfen). Each method was performed in one of the participating laboratories: Bologna, Cremona, Florence, and Padua.<br />Results: Our data confirmed the overestimation of apixaban and rivaroxaban levels by the antithrombin-supplemented anti-Xa method (Berichrom). Performances and reproducibility of the six anti-Xa assays not supplemented with antithrombin and the HPLC-UV method were good, with limits of quantification from 8-39 ng/mL (apixaban) and 15-33 ng/mL (rivaroxaban). The six chromogenic methods showed good concordances with the quantitative HPLC-UV [bias: -26.9-22.3 ng/mL (apixaban), -11.3-18.7 ng/mL (rivaroxaban)]. Higher bias and wider range between limits of agreement were observed at higher concentrations [<100 ng/mL: bias -21.3-4.1 ng/mL (apixaban) and -6.2-3.8 ng/mL (rivaroxaban); >200 ng/mL: bias -42.2-36.8 ng/mL (apixaban) and -20.1-68.9 ng/mL (rivaroxaban)].<br />Conclusion: Overall, the anti-Xa assays not supplemented with antithrombin and the HPLC-UV method proved to be suitable for apixaban and rivaroxaban quantification.<br /> (© 2020 John Wiley & Sons Ltd.)
- Subjects :
- Chromatography, High Pressure Liquid
Factor Xa Inhibitors administration & dosage
Female
Humans
Male
Pyrazoles administration & dosage
Pyridones administration & dosage
Rivaroxaban administration & dosage
Drug Monitoring
Factor Xa Inhibitors pharmacokinetics
Pyrazoles pharmacokinetics
Pyridones pharmacokinetics
Registries
Rivaroxaban pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 1751-553X
- Volume :
- 42
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- International journal of laboratory hematology
- Publication Type :
- Academic Journal
- Accession number :
- 32039550
- Full Text :
- https://doi.org/10.1111/ijlh.13159